FA
DRIO icon

Friess Associates’s DarioHealth DRIO Stock Holding History

Friess Associates’s Portfolio DRIO Stock Details DRIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-18,047
Closed -$5.16M – 101
2020
Q4 		$5.16M Buy
18,047
+11,997
+198% +$3.09M 0.38% 57
2020
Q3 		$2.03M Buy
+6,050
New +$1.64M 0.18% 81

Other funds holding DRIO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
LC
L1 Capital Melbourne VIC 3000, Australia $2.55B AUM 80.12% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
CHM
Collaborative Holdings Management New York $49.2M AUM 119.38% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Friess Associates's DRIO Position: Q1 2021 in Review

Friess Associates sold out of DarioHealth (DRIO) in Q1 2021, closing a stake of 18,047 shares — an estimated $5.16M sold.

Friess Associates first reported a position in DRIO in Q3 2020 and held it in 2 quarters. The position peaked at $5.16M in Q4 2020. 54 funds tracked by Wall St. Rank hold DRIO as of Q1 2021.

  • Friess Associates reported no remaining DarioHealth position as of Q1 2021 after selling out during the quarter.
  • Friess Associates sold 18,047 DarioHealth shares in Q1 2021, an estimated $5.16M.
  • Friess Associates first reported a position in DarioHealth in Q3 2020 and held it in 2 quarters.
  • Friess Associates's DarioHealth position peaked at $5.16M in Q4 2020.
  • 54 funds tracked by Wall St. Rank held DarioHealth as of Q1 2021.

Based on Friess Associates's 13F filing for Q1 2021, filed 14 May 2021.